Drugs / Vacc-C5
Vacc-C5
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01627678 | Sep 2012 → Nov 2013 | HIV infectious disease | Bionor Immuno AS | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vacc-C5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01627678 ↗ |
| Known as | Vacc-C5 = C5-pepide | “Vacc-C5 = C5-pepide” NCT01627678 ↗ |
| Known as | Vacc-C5 = C5-peptide | “Vacc-C5 = C5-peptide” NCT01627678 ↗ |
| Modality | Vaccine | “Vacc-C5, a peptide-based therapeutic vaccine candidate corresponding to C5/gp41732-744” PMID 28340570 ↗ Mar 2017 |
| Route | Other | “Vacc-C5 with GM-CSF as adjuvant administered intradermally.” NCT01627678 ↗ |